Epivax Oncology
Epivax Oncology is a privately held precision cancer immunotherapy company founded in 2017 in Providence, RI, developing personalized cancer vaccines that leverage genomic technology and mRNA platforms to deliver individualized cancer treatments.
- Company typePrivate
- Founded2017
- HeadquartersProvidence, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Epivax Oncology firmographics
Firmographics- Name
- Epivax Oncology
- Website
- https://epivaxtx.com
- Company type
- Private
- Founded year
- 2017
- Headcount range
- 11–50 employees
- Short description
- Epivax Oncology is a privately held precision cancer immunotherapy company founded in 2017 in Providence, RI, developing personalized cancer vaccines that leverage genomic technology and mRNA platforms to deliver individualized cancer treatments.
- Ownership category
- akta.pro rank
Epivax Oncology industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro industry
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)Therapeutic Vaccines (cancer, chronic infection immunotherapy)Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
Keywords
Where Epivax Oncology is headquartered
LocationHeadquarters
- HQ city
- Providence
- HQ country
- United States
- HQ region
- North America
Markets served
Epivax Oncology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Epivax Oncology product offering
Product offeringCore offering
Epivax Oncology develops personalized cancer immunotherapies in the form of patient-specific cancer vaccines. The company combines genomic sequencing, bioinformatics, and mRNA platforms to design targeted vaccines intended to treat patients whose tumors are amenable to individualized neoantigen-based immunotherapy. Core activity is preclinical/early-stage therapeutic vaccine development rather than commercial product sales.
Differentiator
Problem solved
Functional benefit
Companies that use Epivax Oncology
Customer profileSegments1 record
Ideal customer profiles2 records
Epivax Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Epivax Oncology partnerships and signals
Strategic signalScale indicators1 record
Epivax Oncology competitors and assessment
Company assessmentDirect peers
- BioNTech: BioNTech is a leading mRNA-based personalized cancer vaccine developer (notably via its acquisition of Neon Therapeutics and the individualized neoantigen vaccine BNT122). Directly comparable to Epivax Oncology in modality, mechanism, and oncology indication focus.
- Moderna: Moderna is developing mRNA-4157, a personalized neoantigen cancer vaccine in late-stage trials in combination with Merck's Keytruda. It is the most advanced and best-capitalized direct competitor to Epivax Oncology in the personalized cancer vaccine space.
- Gritstone bio: Gritstone bio develops personalized neoantigen cancer vaccines (SLATE and GRANITE programs) using a viral vector prime/self-amplifying mRNA boost approach. It is a closely comparable smaller-cap public peer in personalized cancer immunotherapy.
- CureVac: CureVac is an mRNA technology company developing personalized cancer vaccines alongside its infectious disease work. It is directly comparable to Epivax Oncology as a peer operating in mRNA-enabled personalized cancer immunotherapy.
Emerging players
- Nouscom: Nouscom is a clinical-stage biotech developing personalized neoantigen cancer vaccines using viral vector platforms. It is comparable to Epivax Oncology as a smaller, specialized peer in the personalized cancer vaccine category.
- EpiVax: EpiVax is an immunoinformatics and neoantigen prediction platform company. It is highly relevant as the apparent progenitor/technology source for Epivax Oncology given shared naming, immunoinformatics roots, and personalized cancer vaccine focus.
Broad incumbents
- Personalis: Personalis provides genomic sequencing and ImmunoID platform used to identify neoantigens for personalized cancer vaccines. It is comparable as an enabling infrastructure provider in the personalized oncology vaccine value chain that Epivax Oncology operates in.
- Merck: Merck (via Keytruda) is the dominant checkpoint inhibitor paired with personalized cancer vaccines across the field. It is comparable as the indirect strategic counterparty that defines the combination-therapy opportunity Epivax Oncology would target.
- Genentech (Roche): Genentech/Roche is a major oncology player with active personalized cancer vaccine programs and immunotherapy combinations. It is comparable as a broad incumbent shaping the competitive and partnership landscape for personalized cancer vaccine developers.
- AstraZeneca: AstraZeneca has invested heavily in immuno-oncology combinations and has interest in personalized neoantigen vaccines. It is comparable as a large incumbent acquirer/partner shaping the strategic opportunity set in personalized cancer vaccines.
Market position
Customer concentration
Epivax Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Epivax Oncology leadership team
Management profileNumber of profiles
Profiles1 record
Epivax Oncology funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Epivax Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Epivax Oncology
What does Epivax Oncology do?
Epivax Oncology develops personalized cancer immunotherapies in the form of patient-specific cancer vaccines. The company combines genomic sequencing, bioinformatics, and mRNA platforms to design targeted vaccines intended to treat patients whose tumors are amenable to individualized neoantigen-based immunotherapy. Core activity is preclinical/early-stage therapeutic vaccine development rather than commercial product sales.
When was Epivax Oncology founded?
Epivax Oncology was founded in 2017. It employs 11 to 50 people.
Where is Epivax Oncology based?
Epivax Oncology is headquartered in Providence, United States, in the North America region.
Who are Epivax Oncology's main competitors?
Direct peers on record are BioNTech, Moderna, Gritstone bio and CureVac. Emerging players are Nouscom and EpiVax. Broad incumbents are Personalis, Merck, Genentech (Roche) and AstraZeneca.
Does Epivax Oncology have an API?
No public API is recorded for Epivax Oncology.
What industry is Epivax Oncology in?
Epivax Oncology's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.